Inivata Announces Collaboration with MedStar Health to Utilize Liquid Biopsy to Advance Precision Cancer Genomics
Inivata Knowledge Accumulation Network (IKAN)
Inivata, a global clinical cancer genomics company utilizing an industry-leading liquid biopsy platform to transform patient care, today announces a collaboration under which MedStar and the MedStar Georgetown Cancer Institute will join the Inivata Knowledge Accumulation Network (IKAN).
IKAN is a global network of world-leading cancer centers working in partnership with Inivata to assess the potential of liquid biopsy and circulating tumor DNA (ctDNA) analysis – a tool for oncologists to stratify patients and monitor individual response to treatment. MedStar joins Atrium Health’s Levine Cancer Institute and West Cancer Center as pioneering members of IKAN.
MedStar cares for thousands of cancer patients and survivors through the MedStar Georgetown Cancer Institute, a network of four MedStar hospitals combining forces to advance cancer care throughout metropolitan Washington, D.C. In collaboration with the MedStar Health Research Institute, MedStar is increasing its capabilities in precision cancer genomics.
Stephen R. T. Evans, MD, Executive Vice President for Medical Affairs and Chief Medical Officer for MedStar Health, said:
“By participating in the IKAN, we’ll have access to a critical mass of biological samples and clinical data for use in unique research for our community in the fast emerging ctDNA area,”
Neil Weissman, MD, president of the MedStar Health Research Institute and chief scientific officer for MedStar Health, said:
“Inivata is a global leader in clinical cancer genomics and will greatly expand our ability to conduct gene-based, cancer research.”
Clive Morris, Chief Medical Officer at Inivata, said:
“We are delighted that MedStar and the MedStar Georgetown Cancer Institute, have joined IKAN. Their expertise and capabilities will add to our ability to undertake clinical work to further validate our proprietary ctDNA platform, InVision™, in a range of indications.”
MedStar Georgetown Cancer Institute’s research engine is the Georgetown Lombardi Comprehensive Cancer Center, the area’s only center to earn the National Cancer Institute’s (NCI) distinction as a comprehensive cancer center – one of fewer than 50 in the United States to hold this designation.
Louis M. Weiner, MD, Director of MedStar Georgetown Cancer Institute and Georgetown Lombardi Comprehensive Cancer Center, said:
“We are delighted to be among the first cancer institutes in the world to join IKAN. Together we will work on a variety of clinical projects spread across a broad range of cancer types to accelerate the development and practice of precision cancer genomics.”
Under an initial agreement, MedStar principally will collect lung, breast, colorectal, and pancreatic cancer blood samples at its most active cancer programs throughout the ten-hospital system for research and storage. Blood collection at MedStar Georgetown University Hospital via Inivata’s liquid biopsy platform has already begun and is supporting treatment decisions for lung cancer patients.
Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to transform the care of cancer patients. The Company’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge and reinforced by multiple high caliber publications. Its lead product, InVisionFirst®-Lung, is commercially available and provides molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata is partnering with pharmaceutical and biotechnology companies on InVisionFirst-Lung and its wider platform, which is applicable to a range of cancer types. The Company has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.